Mr. Chair, I can only say that the hon. member is living in a parallel universe that I am not familiar with, because the incredible study that was done in advance of this indicated a $12 billion annual benefit to the Canadian economy.
That actually means more jobs when the economy grows by $12 billion a year. That inevitably means jobs and income opportunities for thousands of Canadian families. That is what the study shows.
I know the member is repeating many of the same concerns that were repeated before the North American Free Trade Agreement and before the Canada-U.S. Free Trade Agreement, that we would lose our culture, which did not happen; that we would lose our health care, but the last I checked, the Obama administration was actually trying to move closer to Canadian health care; that we would lose our system of supply management, but we did not; or that we would lose our fine Baby Duck wine. We actually ended up with better quality Canadian wines.
Throughout all the issues he has raised, he is simply not accurate. He asked me to answer a specific question about provisions that have not even been negotiated yet with regard to pharmaceuticals, issues that are to be negotiated at the table, and we are doing that in a fashion that will defend Canada's interests.
It is important to recognize also that nothing in this agreement will affect the provinces' ability and mandate to deliver health care in the best interests of Canadians.